4 hours ago 2

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital

TipRanks

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital

https://www.tipranks.com/news/the-fly/acadia-nuplazid-patent-ruling-removes-key-overhang-says-bmo-capital

TipRanks

Sat, May 17, 2025, 1:36 PM 1 min read

In This Article:

BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims 4 and 5 of Acadia’s 11,452,721 U.S. formulation patent. Today’s announcement likely extends the lifespan of pimavanserin and could extend the company’s patent protection from 2030 to 2038, removing a “key overhang,” says the analyst, who reiterates an Outperform rating and $24 price target on Acadia shares.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ACAD:

Disclaimer & DisclosureReport an Issue

Recommended Stories

Read Entire Article

From Twitter

Comments